POSC83 Estimating the Clinical and Economic Benefits of Optimising Management of Patients with Hemophilia A in Developing Countries

Abstract

Whilst lifelong high-dose prophylaxis (Px) is considered the optimal standard of care (SOC) for hemophilia A (HA), the perceived high cost and limited access and availability of factor FVIII could limit adoption of high-dose Px. Thus, many developing countries adopt less costly Px management alternatives, including low- and intermediate-dose Px treatment. This study estimates the potential clinical and economic benefits of optimizing Px treatment strategies to improve the SOC in patients with severe HA.